Jul 2026· Small· pp.
e74925
· 0 citations· 70 references
Medicine
TL;DR
This study is the first to integrate a ferrous-supply-regeneration system with siRNA into a single LNP platform, offering a selective ferroptosis-inducing strategy for ocular cancers and other ferroptosis-sensitive malignancies.
Abstract
Targeting iron-dependent ferroptosis with siRNA has emerged as a promising strategy for cancer treatment. The concept of ferrous-supply regeneration, inspired by electro-Fenton technology, has also gained interest as a non-apoptotic approach to induce ferroptosis. However, integrating both strategies into a single lipid nanoparticle (LNP) remains challenging. To address this, we developed ALSF, a novel LNP in which DSPC is replaced with arachidonic acid (AA) to enable co-delivery of Glutathione Peroxidase 4-siRNA (GPX4-siRNA) and Fe3 +. ALSF facilitates acid- and H2O2-dependent iron recycling, continuously regenerating Fe2 + to drive ROS production, while GPX4-siRNA silences GPX4 to induce lipid peroxidation (LPO) and ferroptosis. Elevated H2O2 levels in cancer cells promote selective iron recycling, lysosomal disruption, and siRNA escape, enabling effective gene knockdown at lower doses. In vivo, ALSF suppressed tumor growth in a C918 xenograft model with favorable biosafety. This study is the first to integrate a ferrous-supply-regeneration system with siRNA into a single LNP platform, offering a selective ferroptosis-inducing strategy for ocular cancers and other ferroptosis-sensitive malignancies.
In vitro and in vivo experiments demonstrate that the self-reinforcing cycle between autophagy and ferroptosis significantly enhances tumor suppression and suggests that targeting iron-autophagy crosstalk with nanomaterials represents a promising strategy for cancer treatment.
Chen-Shuo Wang, Zhen-Zhen Ma, Meng-Yu Liu et al.· European journal of pharmace...· 0 citations
The biological rationale for ferroptosis-targeted cancer therapy is summarized, major translational barriers are analyzed, and nanomedicine strategies that may move ferroptosis induction from experimental proof of concept toward clinically interpretable intervention are synthesized.
Yan-Pin Ma, Zi-Yi Xu, Huda Akram et al.· Frontiers in Molecular Biosc...· 0 citations
This work presents a mitochondria-targeted, ROS-activatable supramolecular delivery nanoplatform for self-amplifying redox imbalance and reversing cisplatin resistance for enhanced cisplatin-based cancer therapy.
Ying Liu, Zong-Tao Zhou, Wei Ma et al.· International journal of pha...· 0 citations
A glutathione-responsive metal–organic framework nanoplatform for the co-delivery of curcumin and a GPX4-targeting antisense oligonucleotide (ASO) demonstrated robust anticancer effects in 3D multicellular tumor spheroids with a promoted oxidative imbalance.
Sen Li, Wen-Tao Wang, Yi-Zhang Chen et al.· Langmuir· 0 citations
In vitro and in vivo data demonstrated that these CuPi-SRF-PAA NPs could achieve effective tumor suppression with high biocompatibility and highlights the key roles of combining redox balance disruption and autophagy blockage in tumor therapy.
Y. Ouyang, Ya-Qin Hu, Chun-Mei Chen et al.· ACS Materials Letters· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.